title: Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass.
abstract: We investigated the effect of daily therapy with 1 mcg alfacalcidol (Doss(®)-TEVA/AWD-pharma) on muscle power, muscle function, balance performance and fear of falls in an open, multi-centered, uncontrolled, prospective study on a cohort of patients with reduced bone mass. Among the 2,097 participants, 87.1% were post-menopausal women and 12.9% were men. Mean age was 74.8 years and mean body mass index (BMI) 26.3 kg/m². A total of 75.3% of the study population had osteoporosis, 81% a diagnosis of "increased risk of falls" and 70.1% had a creatinine clearance (CrCl) of <65 ml/min. Participants underwent muscle function and muscle power tests at onset and after 3 and 6 months: the timed up and go test (TUG) and the chair rising test (CRT). At baseline and after 6 months, participants performed the tandem gait test (TGT) and filled out a questionnaire evaluating fear of falling. Successful performance in the muscle tests is associated with a significantly lower risk of falls and non-vertebral fractures in elderly patients (successful test performance: TUG ≤ 10 s (sec), CRT ≤ 10 s, TGT ≥ 8 steps). A significant improvement in the performance of the two muscle tests was proved already after 3 months of treatment with alfacalcidol and further increased by the end of the therapeutic intervention. There were significant increases in the number of participants able to successfully perform the tests: 24.6% at baseline and 46.3% at the end of trial for the TUG (P < 0.0001) and 21.7% at baseline and 44.2% at the end for the CRT test (P = 0.0001). The mean time used for the TUG was decreased by 3.0 s from the average onset value of 17.0 s and by 3.1 s from the initial average 16.5 s for the CRT. The percentage of participants able to perform the balance test (TGT) increased from 36.0% at onset to 58.6% at the end of the trial (P < 0.0001). An increased fear of falling was reduced by the end of the study in 74.4% of the patients. Throughout the study, there were 26 adverse drug reactions in 11 out of 2,097 patients (incidence 0.52%). No serious adverse drug reactions and no cases of hypercalcemia were documented. We conclude that treatment with alfacalcidol is safe, increases muscle power, muscle function and balance and reduces fear of falls. The significant improvement in the three muscle and balance tests and fear of falls may have a preventative effect on falls and fractures. We suggest that the quantitative risk tests used in this study could be reliable surrogate parameters for the risk of falls and fractures in elderly patients.
authors.affiliation: ZORG (Zurich Osteoporosis Research Group), Zollikerberg, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: Schacht
authors.forename: Johann D
authors.initials: JD
authors.lastname: Ringe
mesh_terms: D000058:Accidental Falls / Q000517:prevention & control; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005239:Fear / Q000523:psychology; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D053580:Muscle Strength / Q000187:drug effects* / Q000502:physiology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D004856:Postural Balance / Q000187:drug effects* / Q000502:physiology; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; C008088:alfacalcidol
references.citation: J Am Geriatr Soc. 1995 Jun;43(6):603-9
references.pmid: 7775716
references.citation: J Am Geriatr Soc. 2001 May;49(5):664-72
references.pmid: 11380764
references.citation: Stroke. 1997 Apr;28(4):736-9
references.pmid: 9099188
references.citation: Rheumatol Int. 2009 Aug;29(10):1177-85
references.pmid: 19159932
references.citation: J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84
references.pmid: 16172518
references.citation: J Gerontol A Biol Sci Med Sci. 1999 Jan;54(1):M38-43
references.pmid: 10026661
references.citation: J Nutr Health Aging. 2005 Sep-Oct;9(5):347-51
references.pmid: 16222401
references.citation: Endocr Rev. 1986 Nov;7(4):434-48
references.pmid: 3536463
references.citation: Osteoporos Int. 2003 Jul;14(7):570-6
references.pmid: 12844211
references.citation: Phys Ther. 2000 Sep;80(9):896-903
references.pmid: 10960937
references.citation: N Engl J Med. 1995 Mar 2;332(9):556-61
references.pmid: 7838189
references.citation: Aging Clin Exp Res. 2005 Apr;17(2):133-42
references.pmid: 15977462
references.citation: Age Ageing. 1997 May;26(3):189-93
references.pmid: 9223714
references.citation: Arch Phys Med Rehabil. 1999 Jan;80(1):54-8
references.pmid: 9915372
references.citation: Endocrinology. 2003 Dec;144(12):5138-44
references.pmid: 12959989
references.citation: J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):64-8
references.pmid: 9886454
references.citation: J Am Geriatr Soc. 1991 Feb;39(2):142-8
references.pmid: 1991946
references.citation: Osteoporos Int. 2006;17(9):1318-28
references.pmid: 16788853
references.citation: J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):497-501
references.pmid: 15225827
references.citation: Calcif Tissue Int. 1999 Oct;65(4):295-306
references.pmid: 10485982
references.citation: J Bone Miner Res. 2007 Feb;22(2):203-10
references.pmid: 17059370
references.citation: Clin Sci (Lond). 1979 Feb;56(2):157-61
references.pmid: 477197
references.citation: J Musculoskelet Neuronal Interact. 2005 Jun;5(2):127-34
references.pmid: 15951628
references.citation: Osteoporos Int. 2010 Jul;21(7):1237-45
references.pmid: 19771489
references.citation: BMJ. 2008 Jan 19;336(7636):124-6
references.pmid: 18202065
references.citation: Curr Osteoporos Rep. 2008 Jun;6(2):57-61
references.pmid: 18778564
references.citation: J Rheumatol Suppl. 2005 Sep;76:26-32
references.pmid: 16142848
references.citation: N Engl J Med. 1992 Feb 6;326(6):357-62
references.pmid: 1729617
references.citation: Aging (Milano). 2000 Dec;12(6):455-60
references.pmid: 11211956
references.citation: Eur J Appl Physiol Occup Physiol. 1984;52(3):310-4
references.pmid: 6539684
references.citation: Osteoporos Int. 2005 Mar;16(3):332-8
references.pmid: 15241585
references.citation: J Am Geriatr Soc. 2004 Feb;52(2):230-6
references.pmid: 14728632
references.citation: Osteoporos Int. 2005 Dec;16(12):1683-90
references.pmid: 15933802
references.citation: J Bone Miner Res. 2000 Jun;15(6):1113-8
references.pmid: 10841179
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: Am J Public Health. 1994 Apr;84(4):565-70
references.pmid: 8154557
references.citation: Arch Intern Med. 2007 Jan 22;167(2):133-9
references.pmid: 17242313
references.citation: Age Ageing. 1977 Nov;6(4):201-10
references.pmid: 596307
references.citation: J Clin Endocrinol Metab. 2007 Jan;92(1):51-8
references.pmid: 17032712
references.citation: Osteoporos Int. 2005 Feb;16(2):198-203
references.pmid: 15221207
references.citation: J Bone Miner Metab. 2008;26(6):531-42
references.pmid: 18979152
references.citation: Calcif Tissue Int. 1999 Oct;65(4):337-40
references.pmid: 10485988
references.citation: Osteoporos Int. 1999;9(2):163-70
references.pmid: 10367045
references.citation: J Gerontol A Biol Sci Med Sci. 1998 Mar;53(2):M112-9
references.pmid: 9520917
references.citation: Calcif Tissue Int. 2008 Feb;82(2):102-7
references.pmid: 18239843
references.citation: Kidney Int. 2007 Jan;71(1):31-8
references.pmid: 17091124
references.citation: JAMA. 2004 Apr 28;291(16):1999-2006
references.pmid: 15113819
references.citation: Osteoporos Int. 2004 Apr;15(4):301-10
references.pmid: 14740153
references.citation: Age Ageing. 2003 May;32(3):315-20
references.pmid: 12720619